Pfizer asks US for emergency use of COVID-19 vaccine

Pfizer asks FDA to allow emergency use of its COVID-19 vaccine.

Arutz Sheva North America Staff ,

COVID-19 vaccine
COVID-19 vaccine

Pfizer said on Friday it is asking US regulators to allow emergency use of its COVID-19 vaccine, starting a process that could bring limited first shots as early as next month, The Associated Press reports.

Pfizer and its German partner BioNTech said that protection plus a good safety record means the vaccine should qualify for emergency use authorization.

“Our work to deliver a safe and effective vaccine has never been more urgent,” Pfizer CEO Albert Bourla said in a statement.

The request comes days after Pfizer and BioNTech announced that its vaccine appears 95% effective at preventing mild to severe COVID-19 disease in a large, ongoing study.

Last week, preliminary results showed the Pfizer-BioNTech vaccine for the coronavirus to be 90% effective.

The initial study showed that among the 43,538 total participants, seven days after the second dose was administered - and 28 days after the first dose - the vaccinated group was found to have 90% fewer symptomatic cases of the coronavirus than the control group.

Days later, a rival company, Moderna, announced that its coronavirus vaccine had been rated as being 94.5% effective.

The Moderna tests included 30,000 participants, half of whom were given a placebo, and half of whom were given the vaccine. Of the control group, 90 became infected with the coronavirus, including 11 with severe cases of the virus.

(Arutz Sheva’s North American desk is keeping you updated until the start of Shabbat in New York. The time posted automatically on all Arutz Sheva articles, however, is Israeli time.)